Skip to main content

Fasenra FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 8, 2019.

FDA Approved: Yes (First approved November 14, 2017)
Brand name: Fasenra
Generic name: benralizumab
Dosage form: Injection
Company: AstraZeneca
Treatment for: Asthma

Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the treatment of patients with severe eosinophilic asthma.

Development Timeline for Fasenra

DateArticle
Oct  4, 2019Approval  FDA Approves Fasenra Pen (benralizumab) Pre-Filled Auto-Injector for Self-Administration
Nov 14, 2017Approval  FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.